New oncology findings highlight how biomarker analysis is moving from retrospective validation toward real-time decision support. In relapsed or refractory small-cell lung cancer, a phase I dose-expansion study reported that biomarker-driven tracking helped map AZD2811’s treatment activity, reinforcing the role of molecular readouts in harder-to-treat disease. Separately, preclinical work described a nanomedicine strategy (iRGD-PLGA nanocomplexes) aimed at colon cancer resistance. The delivery platform is designed to improve targeting and overcome chemoresistance—an approach that will be evaluated next in translational and clinical settings. Together, the updates show oncology developers leaning more heavily on measurable molecular endpoints—whether to monitor drug response in trials or to engineer delivery systems to counter resistance mechanisms.